DRMAW — Dermata Therapeutics, Inc.

DRMAWDermata Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · dermatarx.com

0.0102USD-44.26%Mkt Cap: —P/E: —Last update: 2026-06-12

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, incl…

Industry Peers

Biotechnology

VRTX

Vertex Pharmaceuticals Incorporated

Regeneron Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Royalty Pharma Plc Class A

31.84BUSDP/E 29.1

Indicators:|

Key Statistics

Company

Market Cap—

Enterprise Value—

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-7.56M USD

Revenue/Share—

Last Price0.0102 USD

Fiscal Year End—

MR Quarter—

Employees9

CountryUS

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B0.01

EPS (TTM)-2.16

EPS (Forward)—

52W Range

0.01002% of range0.0188

52W High0.0188 USD

52W Low0.0100 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-121.45%

ROA-96.12%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-7.76M USD

CapEx (TTM)—

FCF Margin—

FCF Yield—

Net Debt-6.95M USD

Net Debt/EBITDA—

Balance Sheet

Debt/Equity—

Current Ratio7.09

Quick Ratio6.60

Book Value/Sh1.594 USD

Cash/Share1.727 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.—

Float3.17M

Insiders—

Institutions—

Technical

SMA 50—

SMA 200—

Beta0.69

S&P 52W Chg23.71%

Avg Vol (30d)432

Avg Vol (10d)—

Technical Indicators

RSI (14)1.0

MACD-0.0007

MACD Signal-0.0001

MACD Hist.-0.0005

BB Upper0.0215 USD

BB Middle0.0179 USD

BB Lower0.0143 USD

BB Width40.49%

ATR (14)0.0006 USD

Vol Ratio (20d)—